Sanofi posts Q3 revenue beat as Dupixent sales jump
Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...
Sanofi Earnings Get Boost From Early Vaccine Sales — Update
Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for ...
Sanofi: Q3 Earnings Snapshot
PARIS (AP) — PARIS (AP) — Sanofi (SNY) on Friday reported third-quarter earnings of $3.09 billion. The company said it had net income of $1.23 per share. Earnings, adjusted for non-recurring costs, ...
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, ...
Sanofi profit growth beats market view on early start of vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...
Sanofi Q3 earnings beat market view, boosted by vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...
Regeneron, Sanofi announce presentation of Dupixent Phase 3 data in CSU
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...
Sanofi’s Strategic Moves and Financial Prospects Drive Buy Rating
Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...